SARS-Coronavirus Nucleocapsid Protein (SARS-CoV N) antibody

Catalog No. ABIN6952555

This Mouse Monoclonal antibody specifically detects in ELISA, WB and IF. It exhibits reactivity toward SARS Coronavirus (SARS-CoV).

Quick Overview for SARS-Coronavirus Nucleocapsid Protein (SARS-CoV N) antibody (ABIN6952555)

Target: SARS-Coronavirus Nucleocapsid Protein (SARS-CoV N)

Reactivity: SARS Coronavirus (SARS-CoV)

Host: Mouse

Clonality: Monoclonal

Conjugate: Un-conjugated

Application: ELISA, Western Blotting (WB), Immunofluorescence (IF)

Clone: M88095

Product Details

Purpose: Mouse monoclonal SARS Coronavirus antibody

Specificity: This antibody recognizes the nucleoprotein of the SARS virus

Purification: Protein A chromatography purified IgG fraction

Purity: > 90 %

Immunogen: SARS coronavirus antibody was raised in mouse using nucleoprotein of the SARS virus as the immunogen.

Isotype: IgG1

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

This SARS-CoV Nucleocapside antibody reacts with SARS-CoV protein (ABIN6952561).

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: 10 mM PBS, pH 7.4 with 0.1 % Sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: -20°C

Target Details

Target: SARS-Coronavirus Nucleocapsid Protein (SARS-CoV N)

Alternative Name: SARS-Coronavirus Nucleocapsid Protein

Target Type: Viral Protein

Background: The SARS coronavirus, sometimes shortened to SARS-CoV, is the virus that causes severe acute respiratory syndrome (SARS). On April 16, 2003, following the outbreak of SARS in Asia and secondary cases elsewhere in the world, the World Health Organization (WHO) issued a press release stating that the coronavirus identified by a number of laboratories was the official cause of SARS. Samples of the virus are being held in laboratories in New York, San Francisco, Manila, Hong Kong, and Toronto.